Month: March 2023

Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Ended Q4 with cash, cash equivalents, restricted cash and investments of $118.4M Company to host investor conference call and webcast today, Wednesday, March 22, at 4:30pm ET BURLINGTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2022 and provided a business update.  Business UpdateCommenced launch...

2022 total revenue of $8.2 million, an increase of 20% year-over-year 2022 total OvaSuiteSMvolume of 21,423 units, an increase 23% year-over-year Fourth quarter 2022 cash utilization of $7.1 million Conference Call and Webcast scheduled for today at 4:30 pm Eastern Time AUSTIN, Texas, March 22, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2022. “2022 was a year of tremendous transformation as we focused on our three strategic initiatives: growth, innovation, and operational excellence. While we exited the year a much leaner company in terms of headcount, we achieved many of our most important goals,...

Achieved consolidated Adjusted EBITDA profitability for first-time in LifeMD history Full Year 2022 consolidated revenue of $119.0 million, up 28% from the same year-ago period. Fourth quarter 2022 consolidated revenue of $28.1 million up 3% from the same year-ago period. This figure was impacted by a $2.9 million deferral of telehealth shipments. Adjusted EPS of $0.02, 107% improvement versus the prior year. Subsequent to year end, executed debt financing transaction with Avenue Capital, providing for up to $40 million of total capital and strengthening LifeMD’s long-term capital position. Full Year 2023 guidance of $140-$150 million in consolidated revenue and $12-$18 million of consolidated Adjusted EBITDA.NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company,...

REDWOOD CITY, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the fourth quarter and full year ended December 31, 2022. In 2022, Talis renewed its focus on the women’s and sexual health markets, where there is strong demand for infectious disease testing at the point of care. During the past several months, the Company continued to execute on aligning resources and reduced its monthly cash burn to targeted levels, extending expected cash runway into 2025. “Physicians in women’s and sexual health are eager to test patients at the point of care where treatment can be immediately prescribed...

– Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 – – Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis – – Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable – – Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar – – Conference call and webcast today at 4:30 p.m. ET – SAN JOSE, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended...

Prioritization of core inhibitor candidate ABI-4334 and pausing of core inhibitor candidate ABI-H3733 based on data to date from ongoing clinical Phase 1 studies of both candidates and chronic toxicology observation for ABI-H3733 Phase 1a complete clinical data for all ABI-4334 dose cohorts expected in April 2023 Advancing expanded research portfolio, with additional development candidate nomination anticipated in 2023 and IND/CTA submission for herpesvirus candidate ABI-5366 planned for the first half of 2024SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an update on its investigational next-generation hepatitis B virus (HBV) core inhibitors,...

SILVER SPRING, Md., March 22, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. Business Highlights:Reported $49.2 million of net sales for full year 2022 Fourth quarter 2022 net sales of $12.7 million, representing an increase of 17% in Q4 2022 compared to Q4 2021 Continued strong growth in sales of CanGaroo® and SimpliDerm® which, on an aggregate basis, increased 30% in Q4 2022 compared to Q4 2021 Improved gross margin 8 percentage points to 39% in Q4 2022 compared to Q4 2021 Entered into a U.S. distribution agreement with Sientra for the...

Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to nominate a fourth product candidate by the end of 2023 Corporate prioritization and restructuring result in cash runway into the second half of 2024 SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate...